MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 09-10-2025
Anixa Biosciences Total Assets 2011-2026 | ANIX
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Anixa Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 21.6 M | 25.5 M | 30.4 M | 36.3 M | 9.45 M | 6.29 M | 6.45 M | 8.81 M | 5.63 M | 9.34 M | 9.06 M | 5.44 M | 5.66 M | 8.65 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 36.3 M | 5.44 M | 13.5 M |
Quarterly Total Assets Anixa Biosciences
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.7 M | 17 M | 21.6 M | 22.9 M | 24.4 M | 25.4 M | 25.5 M | 26.6 M | 27.6 M | 35.2 M | 30.4 M | 32.6 M | 32.8 M | 14.6 M | 36.3 M | 37.1 M | 36.3 M | 9.45 M | 9.45 M | 9.45 M | 9.45 M | 6.47 M | 6.29 M | 6.29 M | 6.29 M | 7.49 M | 6.45 M | 6.45 M | 6.45 M | 4.22 M | 8.81 M | 8.81 M | 8.81 M | 8.65 M | 5.63 M | 5.63 M | 5.63 M | 13.3 M | 9.34 M | 9.34 M | 9.34 M | 10.3 M | 9.06 M | 9.06 M | 9.06 M | 7.52 M | 5.44 M | 5.44 M | 5.44 M | 8.03 M | 5.66 M | 5.66 M | 5.66 M | - | 8.65 M | 8.65 M | 8.65 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 37.1 M | 4.22 M | 13.6 M |
Total Assets of other stocks in the Diagnostics research industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
1.77 B | - | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
94.3 M | $ 22.11 | - | $ 99.4 M |  Israel |
 |
Accelerate Diagnostics
AXDX
|
65 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Burning Rock Biotech Limited
BNR
|
2.28 B | $ 22.36 | 17.07 % | $ 241 M |  China |
 |
Biocept
BIOC
|
30.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
62.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
BioNano Genomics
BNGO
|
76.7 M | $ 1.6 | - | $ 2.03 M | USA |
 |
Castle Biosciences
CSTL
|
531 M | $ 40.61 | 1.35 % | $ 1.13 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
235 M | - | - | $ 562 M |  Britain |
 |
Co-Diagnostics
CODX
|
95.3 M | $ 6.03 | - | $ 177 M | USA |
 |
DarioHealth Corp.
DRIO
|
96.4 M | $ 12.13 | -10.01 % | $ 344 M | Israel |
 |
DermTech
DMTK
|
122 M | - | -11.32 % | $ 2.94 M | USA |
 |
Fulgent Genetics
FLGT
|
1.22 B | $ 28.01 | 7.77 % | $ 847 M | USA |
 |
Danaher Corporation
DHR
|
77.5 B | $ 235.57 | - | $ 172 B | USA |
 |
Global Cord Blood Corporation
CO
|
8.53 B | - | - | $ 399 M | China |
 |
DexCom
DXCM
|
6.26 B | $ 70.1 | - | $ 27.1 B | USA |
 |
Fluidigm Corporation
FLDM
|
325 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
20.8 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
975 M | - | 0.12 % | $ 80.1 M | China |
 |
Enzo Biochem
ENZ
|
85.8 M | - | -8.98 % | $ 14.8 K | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
4.18 B | - | - | $ 10.7 B | USA |
 |
Exact Sciences Corporation
EXAS
|
5.93 B | $ 101.63 | - | $ 18.8 B | USA |
 |
CareDx, Inc
CDNA
|
467 M | $ 18.9 | - | $ 1.02 B | USA |
 |
Celcuity
CELC
|
245 M | $ 109.17 | 3.95 % | $ 4.31 B | USA |
 |
Guardant Health
GH
|
1.49 B | $ 109.93 | - | $ 13.5 B | USA |
 |
Aspira Women's Health
AWH
|
17.4 M | - | -6.19 % | $ 10.5 M | USA |
 |
Heska Corporation
HSKA
|
586 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
17.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
IQVIA Holdings
IQV
|
26.9 B | $ 244.29 | 1.58 % | $ 44.3 B | USA |
 |
Illumina
ILMN
|
6.3 B | $ 150.14 | - | $ 23.9 B | USA |
 |
Charles River Laboratories International
CRL
|
7.53 B | $ 216.77 | - | $ 11.1 B | USA |
 |
Mettler-Toledo International
MTD
|
3.24 B | $ 1 470.87 | - | $ 31.2 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
1.03 B | $ 6.63 | - | $ 601 M | USA |
 |
National Research Corporation
NRC
|
122 M | $ 18.9 | -2.07 % | $ 464 M | USA |
 |
Natera
NTRA
|
1.39 B | $ 254.4 | - | $ 25 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 178.14 | - | $ 19.8 B | USA |
|
Biodesix
BDSX
|
97.2 M | $ 5.96 | -1.16 % | $ 773 M | USA |
 |
OPKO Health
OPK
|
2.2 B | $ 1.36 | - | $ 944 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
18.4 B | $ 253.73 | - | $ 21.3 B | USA |
 |
Motus GI Holdings
MOTS
|
7.22 M | - | -34.28 % | $ 263 K | Israel |
 |
ICON Public Limited Company
ICLR
|
16.9 B | $ 202.92 | - | $ 16.7 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
3.29 B | $ 714.55 | - | $ 58.9 B | USA |
 |
Lantheus Holdings
LNTH
|
1.98 B | $ 69.37 | -0.44 % | $ 4.8 B | USA |
 |
Agilent Technologies
A
|
10.7 B | $ 147.81 | 0.14 % | $ 44.9 B | USA |
 |
Biomerica
BMRA
|
5.94 M | $ 2.78 | 5.41 % | $ 6.39 M | USA |
 |
Bioventus
BVS
|
811 M | $ 7.61 | -0.52 % | $ 477 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
29 B | $ 29.12 | - | $ 20 B |  Niderland |
 |
Check-Cap Ltd.
CHEK
|
377 K | - | - | $ 9.42 M | Israel |